Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Drano. Your sure right about yesterday. Sorry I don't have pm privileges
I want to apologize to the board about my ramblings near the end. I'm disheartened like Mr Ehrlich by those who may have lost their investment so fast within 2-3 hours and had been holding for several years. SEEKING ALPHA does have some creditable stuff, but this piece was so negative 96% overvalued a .09 value at best and the misrepresentations. No level playing field as the response could only humanly come a day later.
Hi BigKahuna,
Aloha under the rainbow. Regarding the K ph 1 results revealed today, do you believe a phase 2 specifically targeting ovarian will run a lot faster than the future phase 2 for solid tumor types?
Thnx
I agree. This never should have been released by SA. It would be nice if SA would give companies a chance to rebutt within 3-5 days the lies they support before the article is broken to mainstream media. They're just at times a very sleazy middleman passing along some lying nonsense at times from people with no credentials, a huge investor group motive and supportive of slanderous statements even if they are only opinions (wrong ones) as stated (some investors sell without getting a counter reply from the company to settle the matter straight). A 96% downside and value shares to be 09 cents at best...implying bankruptcy. Give me a break of a lifetime. When the SA writer says its all opinions, he should have been required to say at the very top in 18 point font, "<BOLD RED> WARNING!!! <BOLD RED> in my opinions and my research has not been corroborated by CTIX nor has CTIX been shown this article and had time to respond". Glad yahoo finance shutdown SA. This nonsense has to stop. The real SCAM is the people behind producing the article, those shorties that knew about it and colluded, and SA that was so supportive. They are all SCUM.
I don't understand the verbal takedowns of ctix. Some of you, (won't mention names) are so concerned that a partnership has to happen within what feels like 2-3 months with "the **n to Leo's head" attitude. If your so enamored with yourselves and your verbiage, talk to Leo about it or ask if you can consult for him since your the winning piece by your words for closing out the uplisting and partnership. Give the man Mr L.E. some space to work out the internal growth plans with the added value. Maybe some here are better suited for the Kleenex farm or maybe I'm 100% wrong. We all make mistakes, hopefully looking back these will be smaller mistakes enveloped by a large success.
Blane,
Even if efficacy is shown at 80%, would not Gild be interested in buying Benitec, as it could possibly shorten Gild's current 12 week treatment. What kind of share number dilution is possible (with the IPO). They are trying to raise 70 million??
Looking forward to the high, optimized, frequent doses in future time.
Great thanks so much!
Anyone know how to contact Mr Ehrlich via email?
Agree with you HUGE. To get this designation before Phase 1 completes all data findings next May feels like we got in way ahead of the pack. And this was a stage 4 safety trial with only 1 dose per week and ctix feels Kevetrin is dose dependent. Can't wait for the multi-dosing per week.
#1 may have gone by the wayside for the rest of 2015/2016 after the FDA designation on Kevetrin.
Youssef, I'm very sorry about your sister.
Hope your family stays strong and grows ever closer
in this difficult time.
My prayers to you and those effected.
Her life's influences and goodness lives on in you and may you
live for her in whatever ways you feel are best.
GOD BLESS
Well said BioHedge. Yes, one would think that future news on 3 fronts (drugs) with B having 2 trials (great news already on B-ABSSSI), K soon having 2 trials (additional Bologna), and P starting that some good news 1 - 12 months out will support an uplist action done this May. Ehrlich hopefully can cut a good license deal soon for B-ABSSSI. I think you said months ago a very good deal is better than looking for a spectacular deal (as in looking for the most perfect deal that won't get done).
Yes, with news over next two months should not RS.
It would seem reasonable to wait a few months to see NASDAQ uplisting and news outcome before attempting maybe 1:2 RS.
In the meantime, Mr Ehrlich needs to get the BOM trial started this week or next. We heard December 2014, then soon around early-mid Feb 2015, now the comprehensive update says May. Its time to get either BOM or Prurisol or both started this month.
Yes, it was well researched. I stopped reading over there when a Stockgumshoe comment was made about Kevetrin that the dosage is so high now at 350 mg/m2 that the patients are swimming in it almost sounding like from the biotech forum's ringleader point of view, there is probably not much extra effect at such high levels. There seemed to be a ringleader impatience from the forum that the K trial should wrapup as dosing at too high levels has little effect. That's when I stopped reading over at that forum. CTIX and DF know whats going on dosage wise and what its worth at this point in time, that's why we continue.
StockGumshoe forum's doctor-writer and forum leader was locked in a debate with a forum poster about a company with a cancer drug called imbruvica and the doctor-writer running the biotech forum was not enthused with the $ prospects of this drug in the value perspective of the stock's share price when it was sitting in the $80 per share range. On the other hand, the subscriber to the forum had been a buyer of the stock for several years and thought the stock was still a good value. In the end, the forum subscriber was correct as verification thru ensuing buyout of the company on March 4, 2015 for $21 billion. I think the stock price is close to $256 per share today. Yes, the doctor on the gumshoe forum is a learned man and very caring person (actually helping people with their personal or family medical issues), but he has not always been correct with his picks as two went from $27 all time high and sits now at $2.70 and another went from $14 to $1.50 or so now. Both these biotech companies had only one product in the pipeline that failed. So there you have it, a learned man with great research articles (and I don't mean to discredit him as he has had some great picks), but not always right. There is only one God, look up to heaven
An abundance of thanks for all you both did on this. Appreciate the central placement and the unselfish, huge efforts.
IMHO Expecting a higher floor on this stock when institutions get in.
Hopefully, we are on a more welcoming exchange by next week of Wed/Thur.
This stock is cheap at $370 million cap considering the pipeline and stages and recent B results.
Leo just needs to get a B-ABSSSI license done - hopefully no longer than 3-4 months from phase 3 approval.
Thanks for drawing this out and your article links as well outstanding.
IMHO NASDAQ by next Wednesday/Thursday at the latest. New investors, big money.
Thanks Karin. Perhaps your right about Shapiro's excitement. Hope the poster shows efficacy against several tumor types and maybe higher dose = greater p21 = greater shrinkage and kevetrin's wide band of dosage amount showing stability/efficacy looks very promising for even better results in phase 2 or phase 2/3 with multidosing per week as I hope for as the outcome of the presentation. Wonder how it will work on stage 3 patients later on.
Karin, do you think we will be able to listen to ASCO presentation over the internet live or at a recorded later time?
Yes, that small amount is microscopic.
Looking forward to April/May company happenings and our new life on NASDAQ with a breakout.
Yes, your right - real analyst coverage will help plus institutions investing.
If these are the phase 2b numbers, I'm befuddled why FDA may want 2 trials for phase 3?
I was kindof thinking Friday this week or Tuesday at the latest next week. IMHO
Glad we had the measurement markers last year of the Cubist and Durata Therapeutics deals
while B-ABSSSI is performing well. And these new B indications starting at phase 2.
Thankful again for the news today!
My guess would be the nasdaq uplisting first. Then, the updates of P21 and product pipeline on separate days.
Maybe we'll get uplisting first, then K dosage on a separate day and all the other things later on separate days.
Shortly (in the PR) to me means 3-5 business days. IMHO
Good news today!
Durata Therapeutics was bought out Nov 2014 for 675 million based on dalbavancin for ABSSI. Seems logical that an approved B for ABSSI is at least worth 675 million on a straight sell of this single indication. IMHO Who knows maybe Ehrlich takes 50 million upfront with the right to buy it at 750 million upon approval. Just thinking one of many possibilities.
Advancing drugs deeper into trials and deals with big pharma.
If B is purportedly worth billions, then ctix needs to cut a B licensing or partnership deal by Dec 2015/March 2015.
Hopefully, Mr Ehrlich is working his way towards a deal.
Yes on second thought that is better. Good data speaks loud for awhile. Revision - hope we're on NASDAQ right before or after Copenhagen. And let FDA designations for phase 3 confirm the data presented. :)
It would be nice if the FDA designations for the phase 3 Brilacidin are announced before the Copenhagen conference and when ctix has listed on NASDAQ.
Thanks for answering - sure wish Bologna would rev up soon.
Hi Bigkahuna,
Is it possible for them to do K with
3 patients at 600 and 3 patients at 900
if no SAE at 900, then move to
3 patients at 1200 and
3 patients at 1500
else if no SAE at 600
3 patients at 700 and
3 patients at 800
Not possible to test two dosage amounts in parallel?
The company has been talking more than just the safety profile thru these cohorts. Biotech shows and press releases laid out that there may be decent efficacy. Yes, we'll see, but the idea here is to show enough efficacy in phase 1 so they can achieve FDA breakthrough designation and what tumors react best. So we march on.
Agree - squeeze out as much additional therapeautic effect data as possible while analyzing p21 levels and its gain and effects at these quite higher dosages.
okay gov thanks for the information
Thanks for passing this along. Interesting
You mean FDA regulatory expert in terms of drug manufacturing expertise?
The CEO said he would give updates on the trials (drugs) at the end of the quarter.
Would you like him to ring your doorbell and meet you in person?
IMHO he feels the financial situation has changed in such a secure manner that he can uplist now with supportive news and results next month and in May to justify the stock trading in a stable manner on the NASDAQ.
I hoping the former as well even if only a license for B-ABSSSI.